Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune, Inc. (Nasdaq: ALT) will announce its first quarter 2021 financial results on May 17, 2021. The company, focused on developing intranasal vaccines and therapies, will hold a conference call at 8:30 am ET to discuss these results and provide updates on its business. The call can be accessed via a domestic dial-in at 877-423-9813 or internationally at 201-689-8573, using the conference ID 13719206. Investors can also join the webcast to get insights into Altimmune's pipeline, including its promising COVID-19 vaccine candidate, AdCOVID™.
Altimmune has reported promising preclinical results for its COVID-19 vaccine candidate, AdCOVID. A single intranasal dose of AdCOVID demonstrated sterilizing immunity in the lungs of vaccinated mice, showing no detectable levels of infectious virus after exposure to SARS-CoV-2. This study signifies a potential breakthrough in preventing viral transmission, crucial amid increasing vaccine hesitancy. The ongoing Phase 1 trial is set to deliver topline data in June 2021, assessing safety and immune response, while AdCOVID's features may enhance vaccine acceptance globally.
Altimmune (Nasdaq: ALT) has announced that its management team will present at two significant scientific conferences in May 2021. Scot Roberts, Ph.D. and Dr. Sarah K. Browne will discuss the AdCOVID™ intranasal COVID-19 vaccine at the World Vaccine Congress from May 4-7, 2021. Additionally, Dr. Scott Harris will present on HepTcell™, a therapy for chronic hepatitis B, at the Chronic Hepatitis B Drug Development Virtual Summit on May 5-6, 2021. Presentation materials will be available on the Altimmune website.
AVG Group Sarl has made a strategic investment of approximately NOK 80,000,000 in Alternus Energy Group PLC, bolstering its position in the Nordic renewable energy sector. Alternus aims to become one of the largest pan-European solar operators by the end of the decade. This partnership will enable AVG to provide further financing and expertise in solar technology, enhancing Alternus's operations in Norway. Currently, Alternus has a portfolio of 39 solar parks with over 140 MWp capacity and plans to acquire an additional 1.2 GW of projects by 2023, aiming for over 2 GW by 2025.
Altimmune, Inc. (Nasdaq: ALT) announced results from its Phase 1b trial evaluating the safety and immunogenicity of its intranasal anthrax vaccine candidate, NasoShield. The trial, supported by BARDA, involved 42 healthy volunteers. Key findings indicated significant serum binding antibody responses to the protective antigen compared to placebo. However, responses blocking anthrax toxin were lower than in previous studies with BioThrax. Importantly, 80% of subjects exhibited mucosal IgA responses. The vaccine was well-tolerated. Next steps will involve discussions with BARDA regarding further development funding.
Altimmune, Inc. (Nasdaq: ALT) announced a collaboration with Summit Biosciences to manufacture a metered multidose nasal spray for its COVID-19 vaccine candidate, AdCOVID. This innovation aims to provide an easy vaccination method, especially in high-demand areas, benefiting from room temperature stability. Currently in a Phase 1 trial, AdCOVID is designed to generate systemic and mucosal immunity against SARS-CoV-2. Positive results from preclinical studies show strong immune responses and high protection rates.
Altimmune, Inc. (Nasdaq: ALT) announced promising preclinical results for its intranasal COVID-19 vaccine candidate, AdCOVID. Conducted in collaboration with the University of Alabama at Birmingham and Saint Louis University, the studies demonstrated 100% protection against lethal SARS-CoV-2 challenges in mice and over a 1000-fold reduction in viral replication post-infection. Antibody responses were durable for at least six months. The Phase 1 clinical trial has begun with data expected in Q2 2021, highlighting AdCOVID’s potential as a leading vaccine candidate.
Altimmune, Inc. expands its collaboration with Lonza to establish a dedicated suite for the production of its AdCOVID vaccine candidate at Lonza's Houston facility. This agreement aims to enhance manufacturing capacity for the intranasal COVID-19 vaccine, addressing current supply challenges. Altimmune is in Phase 1 trials of AdCOVID, with data expected in Q2 2021. The vaccine promises easy storage and a potential one-year immunity after a single dose. Preclinical studies suggest significant immune response activation, positioning AdCOVID as a potential leader in COVID-19 vaccination strategies.
Altimmune announced management presentations at two upcoming conferences. A fireside chat at the H.C. Wainwright Global Life Sciences Conference will take place on March 9, 2021, featuring CEO Vipin Garg and other executives. Additionally, Chief Medical Officer Dr. Scott Harris will present at the NASH-TAG Conference on March 13, 2021, discussing dual GLP-1 agonists for treating liver dysfunction in NASH. Webcast links for both events are available on Altimmune's website, providing further insights into their innovative pipeline.
Altimmune, Inc. (Nasdaq: ALT) has initiated enrollment in a Phase 1 clinical trial for AdCOVID, a single-dose intranasal COVID-19 vaccine aimed at generating both systemic and local immunity. The trial targets up to 180 healthy adults aged 18-55 to assess safety and immunogenicity. Results from preclinical studies show promising mucosal immunity responses, crucial for virus transmission prevention. The trial's full data readout is expected by Q2 2021, with the potential for room temperature stability enhancing distribution efficiency.